[Clinical and genetic background of familial myelodysplasia and acute myeloid leukemia]

Orv Hetil. 2016 Feb 21;157(8):283-9. doi: 10.1556/650.2016.30375.
[Article in Hungarian]

Abstract

Myelodysplastic syndrome and acute myeloid leukaemia are mainly sporadic diseases, however, rare familial cases exist. These disorders are considered rare, but are likely to be more common than currently appreciated, and are characterized by the autosomal dominant mutations of hematopoietic transcription factors. These syndromes have typical phenotypic features and are associated with an increased risk for developing overt malignancy. Currently, four recognized syndromes could be separated: familial acute myeloid leukemia with mutated CEBPA, familial myelodysplastic syndrome/acute myeloid leukemia with mutated GATA2, familial platelet disorder with propensity to myeloid malignancy with RUNX1 mutations, and telomere biology disorders due to mutations of TERC or TERT. Furthermore, there are new, emerging syndromes associated with germline mutations in novel genes including ANKRD26, ETV6, SRP72 or DDX41. This review will discuss the current understanding of the genetic basis and clinical presentation of familial leukemia and myelodysplasia.

Keywords: CEBPA; GATA2; MDS; RUNX1; familial leukemia; familiáris leukaemia; germline mutation; germline mutáció.

Publication types

  • English Abstract
  • Review

MeSH terms

  • CCAAT-Enhancer-Binding Proteins / genetics
  • GATA2 Transcription Factor / genetics
  • Genetic Background*
  • Genetic Predisposition to Disease
  • Humans
  • Leukemia, Myeloid, Acute / genetics*
  • Mutation*
  • Myelodysplastic Syndromes / genetics*
  • RNA / genetics
  • Telomerase / genetics
  • Telomerase / metabolism

Substances

  • CCAAT-Enhancer-Binding Proteins
  • CEBPA protein, human
  • GATA2 Transcription Factor
  • GATA2 protein, human
  • telomerase RNA
  • RNA
  • TERT protein, human
  • Telomerase